EI
IMNM icon

EAM Investors’s Immunome IMNM Stock Holding History

EAM Investors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.57M Buy
+71,757
New +$1.6M 0.18% 181
2024
Q2 		– Sell
-127,980
Closed -$3.16M – 294
2024
Q1 		$3.16M Buy
+127,980
New +$2.6M 0.49% 114

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

EAM Investors's IMNM Position: Q1 2026 in Review

EAM Investors opened a new position in Immunome (IMNM) in Q1 2026: 71,757 shares worth $1.57M. The stake represents 0.18% of the portfolio and ranks #181 among its holdings. This is a return to the name: EAM Investors previously reported a position in IMNM as recently as Q1 2024.

EAM Investors first reported a position in IMNM in Q1 2024 and has held it in 2 quarters since. The position peaked at $3.16M in Q1 2024. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • EAM Investors held 71,757 shares of Immunome worth $1.57M as of Q1 2026.
  • Immunome was a new EAM Investors position in Q1 2026.
  • Immunome made up 0.18% of EAM Investors's portfolio in Q1 2026, its #181 holding.
  • EAM Investors first reported a position in Immunome in Q1 2024 and has held it in 2 quarters since.
  • EAM Investors's Immunome position peaked at $3.16M in Q1 2024.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.